$599

New Lilly RNAi Drug Development Collaboration

Lilly announced a new collaboration with Dicerna for the development and commercialization of RNAi therapeutics treating cardio-metabolic disease, neurodegeneration, and pain. It remains unclear if or how this collaboration will impact Lilly’s diabetes business unit. Below, FENIX provides general thoughts on RNAi treatments as well as potential diabetes-related targets that Lilly/Dicerna could be pursuing.

This content is for Read Less members only.
Register
Already a member? Log in here